What is the long-term trend for Xeris Biopharma Holdings, Inc.'s customer receivables and other?

Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s customer receivables and other has grown at a 97.3% compound annual growth rate (CAGR), from $313K to $4.74M.

Xeris Biopharma Holdings, Inc. XERS Customer receivables and Other

Customer receivables and Other at other companies

Morgan StanleyMS

$2.52B+0.4%

McEwen MiningMUX

$385K+6.6%

Raymond James FinancialRJF

$1.81B-3.5%

Chicago Atlantic Real Estate FinanceREFI

$2.56M+388%

Independent Bank CorporationIBCP

$1.04M-33.5%

Arbor Realty TrustABR

$35.25M+267%

Other financials

Income statement

See full

Revenue$83.1M+38.3%

Gross profit$72.6M+41.2%

Operating income$7.9M+356%

Net income$2.2M+124%

EPS (diluted)$0.01+117%

Balance sheet

See full

Cash & equivalents$111.8M+91.2%

Total debt$258.6M-3.8%

Total equity$13.0M+137%

Total assets$392.0M+24.3%

Cash flow

See full

Operating cash flow$9.9M+198%

CapEx$131.0K—

Free cash flow-$29.1M—

Valuation

See full

Market cap$1.28B+76.9%

Enterprise value$1.42B+52.7%

P/E106.4×—

P/S4.1×+0.8×

Profitability

See full

Gross margin85.9%+3.7pp

Operating margin11.4%+7.7pp

Net margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-209.8%—

Debt / equity19.9×—

Current ratio2.1×+0.4×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeOther.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s customer receivables and other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s customer receivables and other?: Xeris Biopharma Holdings, Inc. (XERS) reported customer receivables and other of $1.2M in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s customer receivables and other changed year-over-year?: Xeris Biopharma Holdings, Inc.'s customer receivables and other increased by 2.3% year-over-year, from $1.18M to $1.2M.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s customer receivables and other?: Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s customer receivables and other has grown at a 97.3% compound annual growth rate (CAGR), from $313K to $4.74M.